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ABSTRACT: A hairpin pyrrole-imidazole polyamide (1)
targeted to the androgen receptor consensus half-site was
found to exert antitumor eﬀects against prostate cancer
xenografts. A previous animal study showed that 1, which
has a chiral amine at the α-position of the γ-aminobutyric acid
turn (γ-turn), did not exhibit toxicity at doses less than 10 mg/
kg. In the same study, a polyamide with an acetamide at the β-
position of the γ-turn resulted in animal morbidity at 2.3 mg/
kg. To identify structural motifs that cause animal toxicity, we
synthesized polyamides 1−4 with variations at the α- and β-positions in the γ-turn. Weight loss, histopathology, and serum
chemistry were analyzed in mice post-treatment. While serum concentration was similar for all four polyamides after injection,
dose-limiting liver toxicity was only observed for three polyamides. Polyamide 3, with an α-acetamide, caused no signiﬁcant
evidence of rodent toxicity and retains activity against LNCaP xenografts.
■ INTRODUCTION
Prostate cancer is a major contributor of cancer death in
American males.1 The malignant transformation of prostate
epithelial tissue is caused by an altered pattern of gene
expression driven by the androgen receptor (AR). Clinically,
localized prostate cancer is curable by surgery or radiation.2,3
Advanced prostate cancer is treated with systemic therapies that
target testosterone signaling (enzalutamide, abiraterone),
immunotherapy (sipuleucel T), and taxane-based chemo-
therapy (docetaxel, cabazitaxel).4 These new agents have
shown survival beneﬁts to patients with castration resistant,
metastatic disease. However, all patients will eventually
progress on these drugs. Resistance to the second-generation
antiandrogen enzalutamide and the CYP17 inhibitor abirater-
one may be due to the action of splice variants of AR that lack
the ligand-binding domain (AR-V).5,6 Therefore, therapy
resistant prostate cancer is an unmet clinical need, and novel
systemic therapies are needed in patients after these treatments
have failed.4
Direct interference of AR-driven transcription at the
protein−DNA interface is a strategy that can circumvent
resistance conferred by AR-V. Genomic DNA is the
predominant target of many chemo- and radiotherapies. The
interactions of these therapies with DNA result in the inhibition
of DNA-dependent processes that are overactive in cancer cells,
such as transcription.7−9 While AR-driven transcription can be
inhibited by DNA-targeted agents,10,11 most conventional
DNA-targeted therapeutics are genotoxic and can induce
secondary malignancies.12 DNA-damaging agents may also
contribute to tumor metastasis through eﬀects on non-
cancerous cells in the tumor microenvironment.13 Small
molecules that interact with DNA without genotoxicity could
be a signiﬁcant advance over conventional DNA-targeted
therapeutics.
Pyrrole-imidazole (Py-Im) polyamides are minor groove
binders that have been shown to aﬀect gene expression in a
number of inducible transcription systems.14−20 As noncovalent
DNA-binding oligomers, these compounds form speciﬁc
hydrogen bonds to the minor groove ﬂoor with programmable
sequence recognition and high aﬃnity.21−23 Py-Im polyamides
are toxic to a variety of cancer cell lines, including prostate
cancer, and exhibit no apparent genotoxicity.24 A typical hairpin
oligomer consists of eight aromatic amino acid rings joined in
the middle by a γ-aminobutyric acid (γ-turn).25 While sequence
recognition is predominately directed by the antiparallel pairing
of N-methylpyrrole and N-methylimidazole carboxamides,
structural modiﬁcations to the γ-turn, such as substitution at
the prochiral α- and β-positions, have been shown to inﬂuence
the DNA aﬃnity,26 cell uptake, and the biological activity of
polyamides in both cell culture and animals.27,28
To date, we have reported the pharmacokinetic (PK) proﬁles
of two eight-ring hairpin-polyamides targeted to the androgen
response element half-site 5′-WGWWCW-3′ (W = A or T) in
Received: July 19, 2013
Published: September 9, 2013
Article
pubs.acs.org/jmc
© 2013 American Chemical Society 7449 dx.doi.org/10.1021/jm401100s | J. Med. Chem. 2013, 56, 7449−7457
mice. The oligomers 1 and 4 of primary sequence ImPyPyPy-γ-
ImPyPyPy∼NHMe∼IPA (Figure 1) diﬀer in substitution at the
γ-turn and were found to have distinct PK proﬁles. Both
compounds were bioavailable in serum after intravenous
injection for more than 24 h; however, 4 was found to have
longer retention in both the serum and tissues. Both
compounds were minimally excreted through the feces, but
signiﬁcant renal clearance was exclusive to 4.28 In addition to
diﬀerences in the PK proﬁles, hairpins 1 and 4 also exhibited
diﬀerent degrees of toxicity to female C57BL/6J mice. While
single subcutaneous administrations of 1 in female mice at 2.5
and 5 mg/kg did not adversely aﬀect the animals, escalated
dosing to 10 mg/kg resulted in weight loss greater than 15%. In
comparison, 4 caused acute animal toxicity in addition to
weight loss at 2.3 and 4.5 mg/kg.28 To dissect the diﬀerences in
toxicities, there are two variables on the turn that must be
Figure 1. Chemical structures. (A) Structures of polyamides 1−4. The compounds only vary by the amino substitution on the γ-turn unit. (B) The
preferred DNA binding sequence of the polyamide core. Polyamide 1 is shown bound to the sequence 5′-WGWWCW-3′. Closed circles represent
imidazole units and open circles represent pyrrole units.
Figure 2. Experiment setup of single dose weight curve experiments. (A) Male C57BL/6J mice were allowed to adapt to new cage settings for 3 days
after arrival and then treated with compound. Animal weights were then monitored for 9 days. Humane end point was deﬁned by visible signs of
duress in the animals or weight loss in excess of 15% of original body weight. Weight curves of compounds (B) 1, (C) 2, (D) 3, and (E) 4.
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sorted out (α- versus β-position and amino versus acetamide
substitution).
More recently, oligomer 1 was found to suppress the growth
of LNCaP xenografts in immunocompromised mice after three
subcutaneous injections at 1 mg/kg.24 Thus, a systematic
toxicity study of 1 and related polyamides with modiﬁcations to
the γ-turn may yield structures with reduced animal toxicity. In
addition, an extensive toxicity study of polyamides in animals to
identify target organs of pathology is a necessary step toward
translation of this technology into the clinic.
In this paper, we report the animal toxicity of four
structurally related polyamides with identical Py-Im sequence
but with diﬀerent substitutions at the γ-turn (Figure 1), a
change that does not alter binding sequence preference. We
assessed mouse weight, organ histopathology, and serum
chemistry in wild-type male mice after single and multiple
dosing regimens. Dose-limiting toxicity was observed at the
highest dose for three of the four molecules. From this study,
we have identiﬁed one polyamide that demonstrates no
detectable toxicity by histopathology or serum analysis after
single or repeated subcutaneous injections.
■ RESULTS
Selection of Py-Im Polyamides. We synthesized four
structurally related polyamides (Figure 1) that have an identical
Py-Im sequence ImPyPyPy-γ-ImPyPyPy∼NHMe∼IPA. These
polyamides demonstrate thermal stabilization of DNA duplexes
containing their target sequence (Figure S1, Supporting
Information). Polyamide 1, ImPyPyPy-2-(R)H2Nγ-ImPyPy-
Py∼NHMe∼IPA, suppressed LNCaP xenografts in mice.24
Polyamide 2, ImPyPyPy-3-(R)H2Nγ-ImPyPyPy∼NHMe∼IPA,
diﬀers from 1 in that the γ-turn is substituted at the β-position.
Polyamide 3, ImPyPyPy-2-(R)AcHNγ-ImPyPyPy∼NHMe∼IPA,
diﬀers from 1 in that the primary amine is acetylated.
Polyamide 4, ImPyPyPy-3-(R)AcHNγ-ImPyPyPy∼NHMe∼IPA,
incorporates both changes from 2 and 3. Our previous report in
Figure 3. (A) Histopathology analysis of sacriﬁced animals showed primary organ damage in the kidney and liver for compounds 1, 2, and 4.
Animals treated with 3 did not exhibit signs of organ damage. * represents n = 1. + = mild damage, ++ = moderate damage, +++ = severe damage.
(B) Liver and kidney histopathology of two representative animals treated with compounds 1−4 at 3 mg/kg. Liver: long gray arrow = hepatocellular
apoptosis/necrosis, arrowheads = outline area of bridging hepatocellular necrosis/apoptosis. Kidney: short gray arrow = tubular epithelial
karyomegaly, long gray arrow = tubular epithelial apoptosis/necrosis, short black arrow = tubular epithelial mitoses, long black arrow = tubular
epithelial attenuation. (C) Serum levels of liver damage and kidney damage markers. Signiﬁcantly elevated markers are shaded in gray. * represents n
= 2.
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female mice showed 1 and 4 both circulated in serum after
intravenous injection.28 To determine if 1−4 demonstrated
comparable serum levels after subcutaneous injection, male
C57BL/6J mice were injected with 10 mg/kg each of 1−4 and
blood collected by retroorbital bleed at various time points. All
polyamides were bioavailable and detectable up to 24 h after
subcutaneous injection (Figure S2, Supporting Information).
Escalating Single Dose Subcutaneous Injections. To
determine the acute eﬀects of subcutaneous dosing of 1−4 and
dose-limiting organ toxicities, 8-week-old male C57BL/6J mice
(n = 4 per dosing group) were treated with 1, 3, and 10 mg/kg
1−4 and observed for 9 days and then sacriﬁced (Figure 2).
Representative mice (n = 2 per dosing group unless otherwise
noted) were subjected to histopathology analysis by a
veterinary pathologist. Blood from all mice was sampled and
sent for analysis of serum markers of target organs. Mice treated
with 1 and 2 demonstrated signiﬁcant weight loss only at 10
mg/kg. Polyamide 4 was only tolerated at 1 mg/kg; all mice
treated with 4 at 3 or 10 mg/kg exhibited hunched posture, loss
of mobility, and acute morbidity. Mice treated with polyamide
2 at 10 mg/kg demonstrated similar morbidity. These mice
were euthanized when signiﬁcant duress was apparent. All other
mice, including those treated with 1 at 10 mg/kg and 3 at all
concentrations, demonstrated no change in behavior and
appearance.
Histopathology revealed lesions consistent with toxicity in
the liver, kidney, and spleen in animals receiving a single
injection of polyamides 1, 2, and 4. The most severe lesions
characterized by diﬀuse hepatocellular necrosis and apoptosis
or multifocal bridging hepatocellular necrosis and apoptosis
were identiﬁed in animals treated with polyamide 2 at 10 mg/
kg and polyamide 4 at both 3 and 10 mg/kg, respectively. Mild
hepatocellular necrosis and apoptosis were observed in animals
treated with polyamide 1 at doses of 3 and 10 mg/kg,
polyamide 2 at 3 mg/kg, and polyamide 4 at 1 mg/kg (Figure
3A). Moderate atypical tubular regeneration (karyomegaly,
tubular attenuation, mitotic ﬁgures) and/or tubular epithelial
necrosis and apoptosis were seen in the kidneys of animals
treated with polyamide 2 at 3 mg/kg and polyamide 4 at 3 and
10 mg/kg (Figure 3B). Milder tubular regeneration and
karyomegaly was observed in animals treated with polyamide
1 at 10 mg/kg and polyamide 4 at 1 mg/kg. Mild lymphoid
apoptosis in the white pulp of the spleen was noted in animals
treated with polyamide 2 at 10 mg/kg and polyamide 4 at 3 and
10 mg/kg. Polyamide 3 demonstrated no detectable toxicity at
any dose level tested. No lesions consistent with toxicity were
observed in the gastrointestinal tract, heart, lung, pancreas, or
stomach in any animals.
Because the liver and kidneys were identiﬁed as the target
organs at risk due to toxicity, serum markers for these organ
systems were measured (Figure 3C). Mice treated with
polyamide 1 demonstrated signiﬁcant elevation of AST, ALT,
and total bilirubin at 10 mg/kg, indicative of acute damage to
liver cells, and moderate elevation of ALT at 3 mg/kg.
Elevation of creatinine and blood urea nitrogen (BUN) was not
observed for any dose level of 1. Polyamide 2 treated mice had
severe elevation of AST, ALT, and total bilirubin at 10 mg/kg
and to a lesser extent at 3 mg/kg. These mice also had elevated
BUN at 10 mg/kg. Mice treated with polyamide 4
demonstrated marked and severe elevations of AST, ALT,
and total bilirubin at both 3 and 10 mg/kg. In addition, these
mice had signiﬁcantly elevated creatinine and BUN at 10 mg/
kg and elevated BUN at 3 mg/kg. Mice treated with polyamide
3 demonstrated no elevation of these markers at the dose levels
tested.
In a previous circulation study, it was found that a cyclic form
of a hairpin polyamide targeted to the sequence 5′-
WGGWWW-3′ had increased animal toxicity.29 However, in
addition to the motif change from hairpin to cycle, the γ-turn of
the cyclic compound was also changed from an (R)-2,4-
diaminobutyric acid turn to an (R)-3,4-diaminobutyric acid
turn. To determine if the toxicity is dependent on the
Figure 4. Experiment setup of multidose weight curve experiments. (A) Male C57BL/6J mice were treated with compound once every 3 days.
Animal weights were then monitored for 9 days. Humane end point was deﬁned by visible signs of duress in the animals or weight loss in excess of
15% of original body weight. (B) Weight curves of compounds 1−4. (C) Histopathology analysis of sacriﬁced animals after multiple injections of
compounds 1−4 at 1 mg/kg. + = mild damage, ++ = moderate damage, +++ = severe damage. (D) Serum levels of liver damage and kidney damage
markers after three sc injections of compounds 1−3. Signiﬁcantly elevated markers are shaded in gray.
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polyamide shape or the γ-turn, we synthesized cyclic polyamide
5 (Figure S3, Supporting Information). The compound was
found to be bioavailable after subcutaneous injection at 10 mg/
kg and did not cause signiﬁcant weight loss in animals.
However, compound 5 did aﬀect the kidney and liver and
caused levels of ALT and AST to increase in a dose-dependent
manner.
Multiple-Dose Subcutaneous Injections. In addition to
single dose injections, the eﬀects of repeated dosing of
polyamides 1−4 in mice were examined. In this experiment,
8-week-old male C57BL/6J mice (n = 3 per dosing group)
were treated with 1 mg/kg of polyamides 1−4 by subcutaneous
injection every 3 days, for a cycle of three injections, and then
sacriﬁced 2 days after the ﬁnal injection (Figure 4A). As in the
single dosing experiments, two mice per group were subjected
to histopathology analysis and all blood samples were sent for
analysis. Mice treated with 1−3 demonstrated no loss in weight
or physical morbidities. Two sequential injections of 4 at 1 mg/
kg resulted in dramatic weight loss, loss of mobility, and
hunched posture within 6 days (Figure 4B). These mice were
promptly euthanized.
Histopathology of the mice treated with polyamide 1 and 2
revealed mild multifocal hepatocellular necrosis and apoptosis
in the liver and mild variable tubular attenuation, karyomegaly,
and epithelial necrosis and apoptosis in the kidney. There was
marked hepatocellular necrosis and apoptosis in the liver and
hyaline droplet accumulation in the kidneys of animals treated
with polyamide 4 (Figure 4C). Because mice treated with 4 did
not tolerate two sequential injections at 1 mg/kg, and single
dosing resulted in moderate liver and mild kidney damage at 3
mg/kg, we chose not to test this compound further. Consistent
with the ﬁndings on histopathology, mice treated with 1 and 2
had elevated AST and ALT (Figure 4D). Mice treated with 3
had no histopathologic lesions consistent with toxicity or
alterations in liver and kidney serum markers.
In Vitro Liver Microsomal Stability Assay. Liver
pathology was the most striking abnormality and was most
severe for 4. To assess if liver pathology was related to the
stability of these compounds, we investigated the metabolic
stability of these polyamides to liver microsome isolates.
Stability to human and mouse liver microsomes with and
without NADPH was tested for polyamides 1−4. Polyamide
1−3 all demonstrated high stability (>90% intact) after 1 h
incubations (Table S1, Supporting Information). However, less
than 5% of polyamide 4 remained intact after 1 h incubation
with either human or mouse liver microsomes independent of
the presence of NADPH.
Liver Uptake of Fluorescein−Polyamide Conjugates.
To determine if the chemical modiﬁcations of the γ-turn
corresponding to 1−4 could inﬂuence liver uptake of
polyamides of otherwise identical structure, we synthesized
four polyamide analogous to 1−4, but with ﬂuorescein
isothiocyanate replacing isophthalic acid at the C-terminus
(Figure S4, Supporting Information). Mice treated with FITC−
polyamide conjugate 8, which has a γ-turn substitution identical
to that of 3, demonstrated less nuclear ﬂuorescence in liver
sections than the other FITC−polyamide conjugates (Figure
S5, Supporting Information). Mice treated with FITC−
polyamide conjugate 9, which has the γ-turn corresponding
to 4, demonstrated the most intense nuclear ﬂuorescence in
liver sections.
Cellular Uptake and Cytotoxicity. To determine the
biological activity of 3 in LNCaP cells we ﬁrst looked for
evidence of nuclear localization using ﬂuorescein analog 8. The
ﬂuorescein analog of 1, compound 6, was used as a benchmark.
Confocal microscopy of LNCaP cells incubated with 2 μM of 6
or 8 for 24 h showed robust nuclear localization (Figure 5A).
The viability of LNCaP cells was also reduced in a dose-
dependent manner by 3, with the half-maximal inhibitory
concentration at 2.1 ± 0.3 μM (Figure 5B).
Figure 5. Activity of 3 in LNCaP cells. (A) Nuclear uptake of 6 and 8. (B) Cellular cytotoxicity of 3 toward LNCaP cells after 72 h incubation. (C)
RPB1 protein decreases after treatment with 1 or 3 at 10 μM for 72 h or doxorubicin (D) at 1 μM for 24 h. (D) Cellular level of p53 protein
increases after treatment 1 or 3 at 10 μM for 72 h or D at 1 μM for 24 h. (E) The p53 responsive genes p21, IGFBP3, and GADD45A are induced by
3 in a dose-dependent fashion (concentrations are 1, 3, 10 μM) after 72 h treatment. (F) Alkaline comet assay shows no increase in genomic
fragmentation after prolonged incubation with 3 (48 h, 10 μM). Error bars represents 90% range; boxes represent the upper and lower quartiles and
median.
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Biological Characterization. Previously we found 1 to
aﬀect the RNA polymerase II holoenzyme, leading to the
degradation of the large subunit, RPB1, and increase cellular
p53 protein.24 Similarly, polyamide 3 reduced RPB1 levels
when incubated with LNCaP cells at 10 μM for 72 h (Figure
5C). The level of p53 protein, as well as the transcripts of
several p53 target genes, was also increased after treatment with
3 (Figure 5D,E). In addition, treatment of LNCaP cells with 10
μM of 3 for 48 h did not result in increased DNA damage by
the comet assay (Figure 5F).
Antitumor Activity. Next, we tested the activity of 3
against LNCaP xenografts in immunocompromised mice. Male
NSG immunocompromised mice were engrafted with 2.5
million LNCaP cells. When the tumors reached 200 mm3 (0.5
× L × W2) treatment was initiated. Mice were treated with
either 3 (sc, 1 mg/kg in 20% DMSO/normal saline, n = 14) or
vehicle (20% DMSO/normal saline, n = 14) once every 3 days
for a cycle of six injections. The animals were then sacriﬁced 2
days after the ﬁnal injection (Figure 6A). Both groups of
animals demonstrated minimal weight loss and no signs of
distress during the course of the experiment (Figure 6B). Mice
treated with 3 had smaller tumors than those treated with
vehicle (T/C = 52.4%) (Figure 6C).
To assess the toxicity of the treatment regimen in healthy
animals, male C57BL/6J mice were treated with an identical
regimen as the tumor-bearing mice and were sacriﬁced 2 days
after the ﬁnal injection. Because the liver and kidney were
identiﬁed as the target organs of toxicity in our previous study,
we assessed relevant serum markers for liver and kidney
pathology (Figure 6D). Treated mice demonstrated no
elevations in AST, ALT, total bilirubin, creatinine, or BUN.
To examine if 3 has an eﬀect on circulating blood counts, whole
blood was sampled before treatment and at the time of sacriﬁce.
No signiﬁcant hematologic changes were noted for the total
white blood cell, total red blood cell, hemoglobin, neutrophil,
or lymphocyte count (Figure 6E).
■ DISCUSSION
Py-Im polyamides interfere with DNA-dependent processes,
including transcription, through noncovalent binding to the
minor groove and do not result in signiﬁcant levels of
genotoxicity.24 These characteristics of polyamides may
represent an advancement over current DNA-targeted cancer
therapies, since development of treatment resistance and
secondary diseases has been linked to drug-induced DNA
damage.12,13,30 Our recent demonstration of the antitumor
eﬃcacy of polyamide 1 against LNCaP xenografts raises the
possibility that the Py-Im polyamide technology platform could
be developed into a new class of oncologic therapeutics.24
However, a more thorough understanding of the eﬀects of
selected polyamides in preclinical animal models is required.
Although extensive prior work has demonstrated bioavailability
of hairpin polyamides in rodents,28,31−33 the physiological
eﬀects of polyamides in an animal model have not been
systematically examined. On the basis of our lead polyamide 1,
we synthesized three additional polyamides and varied the γ-
turn. This chemical change does not alter the DNA target
sequence but aﬀects animal toxicity and tissue distribution in
mice.28
We ﬁnd that subtle changes to the substitution on the γ-turn
can dramatically impact systemic toxicity of the selected
polyamides in rodents. In line with previously published
work, compound 1 caused weight reduction in animals treated
at 10 mg/kg but caused no other visible side eﬀects.28
Compound 4 led to pronounced deterioration in the animals’
condition at 3 and 10 mg/kg. Initially, the toxicity associated
with compound 4 was attributed to the acetylation of the
primary amine, since acetylation generally leads to increased
toxicity in cell culture.27 However, the unacetylated version of
4, compound 2, also demonstrated marked toxicity toward the
animals, while the acetylated version of 1, compound 3, showed
no adverse eﬀects, suggesting that the acetylation of the amine
is not the sole contributor to diﬀerences in toxicity.
Furthermore, a previous study reported that a cyclic
polyamide with a (R)-3,4-diaminobutyric acid turn (β-
substitution) was more toxic than its hairpin counterpart,
Figure 6. Activity of 3 against LNCaP xenografts. (A) Timeline of treatment regimen. (B) Mouse weights throughout experiment. (C) Tumor
weights at the experimental end point. Error bars represents maximum and minimum; boxes represent the upper and lower quartiles and median. p <
0.01. (D) Serum chemistry analysis of wild-type mice after six injections of 3. Serum levels of AST, ALT, total bilirubin, BUN, and creatinine were
found to be within normal limits after compound treatment. (E) Hematological analysis of wild-type mice after six injections of 3. The levels of white
blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), neutrophil, and lymphocytes were not signiﬁcantly aﬀected by polyamide treatment.
Values represent average of ﬁve animals, and errors are std.
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which possessed a (R)-2,4-diaminobutyric acid turn (α-
substitution). To see if the cyclic version of 1 led to increased
animal toxicity, we synthesized 5. This compound was
detectable in the serum after sc injection and was found to
have less eﬀect on animal weight than 1. This suggests that the
increase in polyamide-induced toxicity is associated with the
transition of the (R)-2,4-diaminobutyric acid turn to the (R)-
3,4-diaminobutyric acid turn. Whether this is a general ﬁnding
for the entire class of Py-Im polyamides remains to be seen.
To identify the cause of animal morbidity we conducted
histopathological analysis on sacriﬁced animals. We found the
liver and kidney to be the main organs of pathology for
compounds 1, 2, 4, and 5. Compound 3 caused no detectable
organ damage. Liver damage was most pronounced for 2 at 10
mg/kg and 4 at 3 and 10 mg/kg. Compound 5 caused
moderate damage to both the liver and kidney at 3 and 10 mg/
kg. We further conﬁrmed our histopathology results with serum
measurements of ALT, AST, total bilirubin, BUN, and
creatinine. The liver damage markers ALT and AST were
signiﬁcantly elevated at higher doses of 1, 2, 4, and 5. Blood
urea nitrogen levels were found to be elevated for 2 at 10 mg/
kg and 4 at 3 and 10 mg/kg.
In addition to single dose experiments we also examined the
eﬀects of 1−4 on animal health after multiple treatments with
an injection regimen that was identical to the treatment cycle
used in our previous xenograft study.24 We found that
compounds 1−3 had minimal eﬀect on animal weight over
three injections of 1 mg/kg, while compound 4 caused acute
distress in the animals after two injections. Histopathology and
serum marker analysis was able to detect liver and kidney
damage in animals treated with all compounds except 3.
Since the liver is most aﬀected by polyamides, we speculated
that enzymatic degradation of the compounds may contribute
to animal toxicity. To test the stability of compounds 1−4 in
the liver we conducted microsomal degradation assays with
human and mice liver microsomes. Compounds 1−3 were
found to be >90% intact after a 60 min incubation with 1 mg/
mL of microsomes. Therefore, the reduced liver toxicity of 3 as
compared to 1, 2, and 4, may not be explained on the basis of
diﬀering stability to liver microsomes. Interestingly, while 4 was
previously reported to be stable against rat and human
microsomes,34 less than 5% of compound 4 remaining at the
end of the assay. This may be explained by the lower amount of
enzyme (0.3 mg/mL) used in the previous assay.
The tissue distribution of Py-Im polyamides is aﬀected by
structure.28,35 In our previous pharmacokinetic study we
showed that 4 had greater localization in the lung, liver, and
kidney than 1.28 Thus, diﬀerences in liver uptake of compounds
1−4 may contribute to the diﬀerences in animal toxicity. To
visualize nuclear uptake we synthesized ﬂuorescein analogues of
1−4. Of the four compounds, 8 (the ﬂuorescein analogue of 3)
showed the least amount of nuclear localization, which may
explain the apparent lack of animal toxicity. A detailed
pharmacokinetic analysis of 2 and 3 could provide more
information on the structure-dependent bioavailability of these
compounds. However, it remains a challenge for the ﬁeld
whether predictable correlation between polyamide structure
and tissue distribution can be achieved.
Polyamide 1 was shown to exert cellular toxicity, in part,
through the inhibition of transcription.24 In line with previous
work, polyamide 3, was also found to aﬀect the cellular level of
RPB1 and p53, which suggests that the cytotoxic eﬀects of 3
also stem from transcription inhibition. Furthermore, no
increased DNA fragmentation was observed when cells were
treated with 3, indicating that the compound interferes with
transcription in a nongenotoxic manner.
In addition to exhibiting similar biological activity in cell
culture and having reduced animal toxicity, 3 also demonstrated
antitumor activity toward LNCaP xenografts. Tumor-bearing
animals and wild-type animals were able to sustain six injections
of 3 without showing any signs of duress. Further character-
ization of serum chemistries and hematology markers indicates
compound 3 is well-tolerated by the animals.
In conclusion, we have identiﬁed a structural motif that
aﬀects the animal toxicity of Py-Im polyamides. The transition
of the (R)-2,4-diaminobutyric acid turn to a (R)-3,4-
diaminobutyric acid turn signiﬁcantly increases the animal
liver and kidney damage caused by polyamides in this study.
From the four compounds, we have identiﬁed polyamide 3,
which contains an acetamide at the α-position of the turn unit
and demonstrates no detectable animal toxicity at 10 mg/kg.
This compound behaves similarly to 1 in cell culture and
retains antitumor activity toward LNCaP xenografts. This
second-generation hairpin polyamide provides a promising lead
for the development of Py-Im polyamides as anticancer
therapeutics.
■ EXPERIMENTAL SECTION
Synthesis of Polyamides. Py-Im polyamides 1−4 and 6−9 were
synthesized on Kaiser oxime resin (Novabiochem) as previously
described.15,36 Complete oligomers were cleaved from resin using 3,3′-
diamino-N-methyldipropylamine and puriﬁed by reverse-phase HPLC
in 0.1% aqueous TFA and acetonitrile.37 Isophthalic acid and
ﬂuorescein isothiocyanate conjugates were synthesized as previously
described.38 Cyclic polyamide 5 was synthesized on 2-chlorotrityl
chloride resin (Bachem) as previously described.39 Deprotection of the
γ-turn was performed as described.26 Hairpin polyamides 3, 4, 8, and 9
were acetylated as previously described.26,34 Polyamides 1−9 were
puriﬁed again by reverse-phase HPLC after ﬁnal conjugation. All
polyamide molecular weight was measured by MALDI-ToF mass
spectrometry (Table S2, Supporting Information), and a compound
purity of >95% was determined by analytical HPLC.
Chemicals and Animals. Ten percent neutral buﬀered formalin
was purchased from Richard-Allan Scientiﬁc, and 6−8-week-old male
C57BL/6J mice were purchased from Jackson Laboratories.
Thermal Denaturation Assay. Thermal stabilization of the DNA
oligo 5′-TTGCTGTTCTGCAA-3′ by 1−4 (target sequence under-
lined) was determined as previously described.26
Animal Weight Loss Analysis. All animal experiments were
conducted under an approved protocol at the California Institute of
Technology. Animals were allowed to adjust for 3 days after arrival
before treatment. Compounds were quantiﬁed with a UV/vis
spectrophotometer using an extinction coeﬃcient of 69 500 M−1·
cm−1 at λmax near 315 nm. For single injection weight loss experiments,
the animals were separated into three treatment groups receiving 1, 3,
or 10 mg/kg of compound in up to 200 μL of a 25% DMSO/saline
vehicle, with four animals per group. Animals were monitored daily for
weight loss over 9 days and sacriﬁced. For repeated injection
experiments the animals were separated into groups of three and
injected with 1 mg/kg of 1−4 once every 3 days and sacriﬁced 2 days
after the last injection. Weight was recorded on days of injection and at
the experiment end point.
Animal Histopathology Analysis. Sacriﬁced animals from weight
loss experiments were ﬁxed in 10% formalin and sent for
histopathology analysis by IDEXX-RADIL. Histopathologic analysis
was performed on the cecum, duodenum, heart, ileum, kidney, liver,
lung, pancreas, spleen, and stomach. Tissue analysis was performed as
a blind study to the identity of the animals.
Serum Analysis. Serum from treated animals were collected by
retroorbital bleeding. Blood samples were centrifuged at 6000 rpm for
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5 min to collect the serum. Serum ALT, AST, total bilirubin, BUN,
and creatinine levels were sent for analysis at IDEXX-RADIL. Serum
analysis was performed as a blind study as to the identity of the
animals. For hematology analysis, blood was collected from ﬁve male
C57BL6/J mice by retroorbital bleed and sent for hematological
analysis in K2EDTA-coated BD Microcontainers. The animals were
allowed to recover for 1 week before treatment with 3 using the same
injection conditions as the NSG mice. At the treatment end point the
animals were bled again and euthanized. Blood samples for serum
chemistry analysis and hematology analysis were prepared separately.
All samples were sent for analysis at IDEXX-RADIL.
Liver Microsomal Stability Analysis. Liver microsomal stability
of 1−4 was performed by Apredica. Brieﬂy, each polyamide was
incubated with 1 mg/mL human or mouse microsomes at 37 °C. The
reaction was incubated in 100 mM KH2PO4, 2 mM NADPH, 3 mM
MgCl2 at pH 7.4. Samples were also incubated in the absence of
NADPH to detect NADPH-free degradation. After 60 min the samples
were mixed with an equal volume of ice-cold methanol stop solution.
The mixture was allowed to sit on ice for at least 10 min and mixed
with an equal volume of water. The samples were then centrifuged to
remove the precipitates and the samples were analyzed by LC/MS/
MS. Data represents percent remaining by comparing with time zero
concentration. The experiments were performed in duplicate.
Tissue Distribution of Fluorescein Tagged Polyamides. Male
C57BL/6J mice (n = 2 per group) were injected with 50 nmol (∼3
mg/kg) of 6−9 and then sacriﬁced 24 h later. Tissue was excised and
processed as previously described.20 The tissues were excised and ﬁxed
in 10% neutral buﬀered formalin for 48 h. They were subsequently
cryoprotected in 15% and 30% aqueous sucrose solution (w/v) for 24
h each, embedded in a medium for frozen sections (Sakura) and
frozen on dry ice. Fluorescence intensity in liver tissue was assessed by
laser confocal microscopy in 10 μm thick sections on slides mounted
with a ProLong antifade reagent (Invitrogen).
Cell Viability Assays. LNCaP cells were plated in clear bottom 96-
well plates at 5000−7500 cells per well and allowed to adhere for 36−
48 h. Compounds were then added in fresh media. Cell metabolic
activity was determined by the WST-1 assay (Roche) after 72-h
incubation with cells. Quantiﬁcation was performed on a Perkin-Elmer
Victor 3 plate reader. Assays were performed in biological triplicates.
Protein ELISA Assays. Cellular levels of RPB1 and p53 protein in
LNCaP cells after treatment with 10 μM 3 for 72 h were determined
by ELISA. Cells treated with DMSO vehicle and 1 μM doxorubicin for
24 h were used as control. Cellular RBP1 levels were determined by a
RPB1-speciﬁc ELISA kit (Cusabio Life Sciences) according to the
manufacturer’s instructions. Total cellular p53 protein level was
determined with a pan-p53 ELISA kit (Roche) according to
manufacturer’s instructions. Assays were performed in biological
triplicates.
Quantitative RT-PCR. LNCaP cells were plated in 12-well plates
at 50 000 cells per well and allowed to adhere for 36−48 h. The cells
were then treated with 1, 3, and 10 μM of 3 for 72 h. Total cellular
RNA was extracted using RNEasy columns (Qiagen) following the
manufacturer’s protocols. Isolated RNA was reverse transcribed with
Transcriptor First Strand cDNA kit (Roche). Quantitative real-time
PCR was performed using SYBR Green PCR Master Mix (Applied
Biosystems) on an ABI 7300 instrument. Ampliﬁcation of p21,
IGFBP3, and GADD45A cDNA was measured relative to β-
glucuronidase using previously published primers.24 Experiments
were performed in biological replicates.
Comet Assay. LNCaP cells were plated in six-well plates at 100
000 cells per well and allowed to adhere for 36−48 h. The cells were
then incubated with either 10 μM 3 for 48 h or 5 μM doxorubicin for 4
h. DNA damage was assayed using the Trevigen CometAssay system.
Cells were harvested by gentle aspiration with PBS and prepared on
slides according to the manufacturer’s protocol. Comet slides were
imaged on a confocal microscope (Exciter, Zeiss) at 10×
magniﬁcation. Images were scored using Comet Assay Lite IV
(Perceptive Instruments). More than 100 comets were scored for
each condition. DNA damage is reported as percentage of DNA in the
tail.
In Vivo Xenograft Experiments. Mice experiments were
conducted under an approved protocol by the Institutional Animal
Care and Use Committee of the California Institute of Technology.
Male C57BL6/J mice and male NSG mice were purchased from The
Jackson Laboratory. All animals were maintained on a standard light−
dark cycle. LNCaP cells (2.5 million cells) were engrafted in a mixture
of 1:1 media and matrigel in the left ﬂank of NSG mice. Tumors were
allowed grow to ∼200 mm3 (0.5 × L × W2) before treatment. Py-Im
polyamide 3 was administered by sc injection once every 3 d at 1 mg/
kg in a 20% (v/v) DMSO:normal saline vehicle solution for six
injections. Animals were sacriﬁced 2 days after the ﬁnal injection.
Animal weight and general health were monitored daily. Fourteen
animals were used for each treatment group.
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